Home > Browse Research > Life Sciences > Pharmaceuticals > Therapeutic Area > Women's Health

Women's Health: market research reports

Women's Health market research reports and industry analysis

Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020 2/29/2012 \| published by: GlobalData ... is an essential source of information and analysis on the global ovarian cancer therapeutics market. The report provides comprehensive information on ovarian cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping ... \| read more...	$6,995.00
Vaginitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 2/29/2012 \| published by: GlobalData ... essential source of information and analysis on the global Vaginitis Infection Therapeutics market. The report identifies the key trends shaping and driving the global Vaginitis Infection Therapeutics market. The report also provides insights on the ... \| read more...	$3,995.00
Post Menopausal Osteoporosis Global Clinical Trials Review, H1, 2012 2/20/2012 \| published by: GlobalData ... provides elemental information and data relating to the clinical trials on Post Menopausal Osteoporosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the ... \| read more...	$1,000.00
Breast Cancer (Metastatic HER2-Positive): Emerging Agents Will Fulfill Efficacy Benefits Expected by Oncologists for First-Line Patients, but Will Escalating Costs Inhibit Their Uptake? 2/1/2012 \| published by: Decision Resources ... disease market have failed to improve survival in the first-line setting. The development pipeline for HER2-positive CaB is competitive, with many developers targeting this well-defined subpopulation. Decision Resources anticipates the approval of three new targeted ... \| read more...	$10,000.00
Metastatic Breast Cancer Global Clinical Trials Review, H1, 2012 1/27/2012 \| published by: GlobalData ... provides elemental information and data relating to the clinical trials on Metastatic Breast Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the ... \| read more...	$1,000.00
Fallopian Tube Cancer - Pipeline Review, H1 2012 1/23/2012 \| published by: Global Markets Direct ... the therapeutic development for Fallopian Tube Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer. 'Fallopian Tube ... \| read more...	$500.00
Breast Cancer - Pipeline Review, H1 2012 1/23/2012 \| published by: Global Markets Direct ... for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. 'Breast Cancer - Pipeline Review, H1 2012' ... \| read more...	$500.00
Vulvovaginal Candidiasis - Pipeline Review, H1 2012 1/23/2012 \| published by: Global Markets Direct ... for Vulvovaginal Candidiasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vulvovaginal Candidiasis. 'Vulvovaginal Candidiasis - Pipeline Review, H1 2012' ... \| read more...	$500.00
Ovarian Cancer - Pipeline Review, H1 2012 1/23/2012 \| published by: Global Markets Direct ... for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. 'Ovarian Cancer - Pipeline Review, H1 2012' ... \| read more...	$500.00
Metastatic Breast Cancer - Pipeline Review, H1 2012 1/23/2012 \| published by: Global Markets Direct ... the therapeutic development for Metastatic Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer. 'Metastatic Breast ... \| read more...	$500.00
Endometrial Cancer - Pipeline Review, H1 2012 1/23/2012 \| published by: Global Markets Direct ... for Endometrial Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Endometrial Cancer. 'Endometrial Cancer - Pipeline Review, H1 2012' ... \| read more...	$500.00
Women's Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market 1/1/2012 \| published by: GBI Research ... has released its latest research “Women’s Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market”. The report provides ... \| read more...	$3,500.00
Herceptin (Breast Cancer) – Analysis and Forecasts to 2020 12/31/2011 \| published by: GlobalData ... detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer market. This report is built ... \| read more...	$2,000.00
Tykerb (Breast Cancer) – Analysis and Forecasts to 2020 12/31/2011 \| published by: GlobalData ... detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer market. This report is built ... \| read more...	$2,000.00
Halaven (Breast Cancer) – Analysis and Forecasts to 2020 12/31/2011 \| published by: GlobalData ... detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Breast Cancer market. This report is built ... \| read more...	$2,000.00
Avastin (Breast Cancer) – Analysis and Forecasts to 2020 12/31/2011 \| published by: GlobalData ... detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer market. This report is built ... \| read more...	$2,000.00
Afatinib (Breast Cancer) - Analysis and Forecasts to 2020 12/31/2011 \| published by: GlobalData ... detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2017-2020). The report also includes information on Breast Cancer market. This report is built ... \| read more...	$2,000.00
Femara (Breast Cancer) – Analysis and Forecasts to 2020 12/31/2011 \| published by: GlobalData ... detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer market. This report is built ... \| read more...	$2,000.00
Omnitarg (Breast Cancer) – Analysis and Forecasts to 2020 12/31/2011 \| published by: GlobalData ... clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer market. This report is built using ... \| read more...	$2,000.00
Arimidex (Breast Cancer) – Analysis and Forecasts to 2020 12/31/2011 \| published by: GlobalData ... detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer market. This report is built ... \| read more...	$2,000.00
Aromasin (Breast Cancer) – Analysis and Forecasts to 2020 12/31/2011 \| published by: GlobalData ... detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the estimate period (2002-2020). The report also includes information on Breast Cancer market. This report is built ... \| read more...	$2,000.00
Faslodex (Breast Cancer) – Analysis and Forecasts to 2020 12/31/2011 \| published by: GlobalData ... detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the estimate period (2002-2020). The report also includes information on Breast Cancer market. This report is built ... \| read more...	$2,000.00
Nolvadex (Breast Cancer) – Analysis and Forecasts to 2020 12/31/2011 \| published by: GlobalData ... detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forcast period . The report also includes information on Breast Cancer market. This report is built ... \| read more...	$2,000.00
T-DM1 (Breast Cancer) – Analysis and Forecasts to 2020 12/31/2011 \| published by: GlobalData ... detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Breast Cancer market. This report is built ... \| read more...	$2,000.00
Zoladex (Breast Cancer) – Analysis and Forecasts to 2020 12/31/2011 \| published by: GlobalData ... detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer market. This report is built ... \| read more...	$2,000.00

< prev 1 2 3 4 5 6 7 8 9 10 next >